MDxHealth SA (NASDAQ:MDXH) Short Interest Down 23.1% in February

MDxHealth SA (NASDAQ:MDXH) saw a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 22,470 shares, a drop of 23.1% from the January 29th total of 29,229 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 96,543 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 96,543 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are short sold.

MDxHealth Trading Up 0.9%

Shares of MDXH traded up $0.03 during mid-day trading on Monday, hitting $3.43. The company’s stock had a trading volume of 82,435 shares, compared to its average volume of 130,502. The firm has a market capitalization of $169.79 million, a P/E ratio of -5.12 and a beta of 1.61. MDxHealth has a 1-year low of $1.35 and a 1-year high of $5.33. The firm has a 50-day simple moving average of $3.55 and a 200 day simple moving average of $3.77.

MDxHealth (NASDAQ:MDXH) last announced its earnings results on Thursday, February 26th. The company reported $999.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $999.13. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The firm had revenue of $29.55 million for the quarter, compared to analyst estimates of $26.05 million. As a group, sell-side analysts predict that MDxHealth will post -1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

A number of institutional investors have recently modified their holdings of the stock. Intesa Sanpaolo Wealth Management bought a new position in shares of MDxHealth in the fourth quarter worth $36,000. GSA Capital Partners LLP bought a new stake in MDxHealth during the third quarter worth approximately $48,000. Lido Advisors LLC bought a new position in MDxHealth during the 3rd quarter valued at $48,000. Squarepoint Ops LLC acquired a new position in shares of MDxHealth during the 4th quarter valued at $51,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of MDxHealth in the third quarter valued at $53,000.

Analysts Set New Price Targets

MDXH has been the topic of a number of analyst reports. Lake Street Capital raised their price objective on shares of MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. BTIG Research reissued a “buy” rating and issued a $7.00 price target on shares of MDxHealth in a research note on Tuesday, December 23rd. TD Cowen raised their price objective on shares of MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.